633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial.
Saved in:
| Title: | 633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial. |
|---|---|
| Authors: | Fizazi, K.1 (AUTHOR), Shore, N.2 (AUTHOR), Smith, M.R.3 (AUTHOR), Tammela, T.L.4 (AUTHOR), Le Berre, M-A.5 (AUTHOR), Petrenciuc, O.6 (AUTHOR), Zurth, C.7 (AUTHOR), Kuss, I.7 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS522-S522. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.892 |
